Peter Marks (AP Photo/Susan Walsh, Pool)
FDA's Peter Marks lays out plans to support gene therapies for ultra-rare diseases
It’s rare to hear an FDA leader say that the use of randomized controlled trials “borders on the absurd.”
But that’s what CBER director Peter …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
